American Bitcoin Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that American Bitcoin Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $185.16M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $71.54M | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | $64.98M | Mar 27, 2026 |
| FY2023 | Dec 31, 2022 | $10.46M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $17.63M | Mar 21, 2023 |
| FY2021 | Oct 1, 2021 | $2.40M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $7.82M | Mar 31, 2022 |
| FY2021 | Jun 30, 2020 | $12.57M | Mar 31, 2022 |
| FY2020 | Jun 30, 2019 | $10.82M | Sep 29, 2020 |
| FY2019 | Mar 31, 2019 | $2.33M | Sep 23, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $3.44M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $5.55M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $10.19M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $4.68M | Mar 31, 2022 |
| FY2020 | Jul 30, 2020 | $5.18M | Sep 29, 2020 |
| FY2021 | Jun 30, 2020 | $6.36M | Mar 31, 2022 |
| FY2020 | Mar 31, 2020 | $1.67M | Sep 29, 2020 |
| FY2020 | Dec 31, 2019 | $1.69M | Sep 29, 2020 |
| FY2020 | Sep 30, 2019 | $1.81M | Sep 29, 2020 |
| FY2020 | Jun 30, 2019 | $6.19M | Sep 29, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($153.17M) | Mar 27, 2026 |
| FY2025 | Mar 31, 2025 | ($100.62M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $428.94M | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | $39.61M | Mar 27, 2026 |
| FY2023 | Dec 31, 2022 | ($79.06M) | Apr 1, 2024 |
| FY2021 | Dec 31, 2021 | $400.0K | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | ($16.21M) | Mar 31, 2022 |
| FY2021 | Jun 30, 2020 | ($13.57M) | Mar 31, 2022 |
| FY2020 | Jun 30, 2019 | ($12.40M) | Sep 29, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($227.99M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $484.10M | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | $6.24M | Mar 27, 2026 |
| FY2023 | Dec 31, 2022 | ($43.08M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($33.11M) | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | ($15.74M) | Mar 31, 2022 |
| FY2021 | Jun 30, 2020 | ($17.27M) | Mar 31, 2022 |
| FY2020 | Jun 30, 2019 | ($12.51M) | Sep 29, 2020 |
| FY2019 | Jun 30, 2018 | ($2.46M) | Sep 23, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $2.34M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $4.09M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $5.89M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $3.17M | Mar 31, 2022 |
| FY2020 | Jul 30, 2020 | $2.11M | Sep 29, 2020 |
| FY2021 | Jun 30, 2020 | $3.21M | Mar 31, 2022 |
| FY2020 | Mar 31, 2020 | $874.8K | Sep 29, 2020 |
| FY2020 | Dec 31, 2019 | $623.5K | Sep 29, 2020 |
| FY2020 | Sep 30, 2019 | $610.9K | Sep 29, 2020 |
| FY2020 | Jun 30, 2019 | $5.57M | Sep 29, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Jul 30, 2020 | $14.16M | Sep 29, 2020 |
| FY2020 | Mar 31, 2020 | $5.68M | Sep 29, 2020 |
| FY2020 | Dec 31, 2019 | $4.88M | Sep 29, 2020 |
| FY2020 | Sep 30, 2019 | $3.60M | Sep 29, 2020 |
| FY2019 | Jun 30, 2019 | $13.14M | Sep 23, 2019 |
| FY2019 | Jun 30, 2018 | $5.93M | Sep 23, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($79.61M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($54.03M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | ($55.97M) | Mar 27, 2026 |
| FY2023 | Dec 31, 2022 | ($10.90M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($8.17M) | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | ($8.71M) | Mar 31, 2022 |
| FY2021 | Jun 30, 2020 | ($14.35M) | Mar 31, 2022 |
| FY2020 | Jun 30, 2019 | ($9.05M) | Sep 29, 2020 |
| FY2019 | Jun 30, 2018 | ($3.74M) | Sep 23, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $6.61M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.89M | Mar 31, 2025 |
| FY2022 | Dec 31, 2022 | $31.9K | Mar 21, 2023 |
| FY2022 | Dec 31, 2021 | $39.3K | Mar 21, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.25B | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.11B | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $18.83M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $19.47M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $94.48M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $77.17M | Mar 31, 2022 |
| FY2020 | Jun 30, 2020 | $58.53M | Sep 29, 2020 |
| FY2020 | Jun 30, 2019 | $24.20M | Sep 29, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $580.69M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $91.33M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $19.43M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $24.29M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $34.53M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $19.95M | Mar 31, 2022 |
| FY2020 | Jun 30, 2020 | $21.96M | Sep 29, 2020 |
| FY2020 | Jun 30, 2019 | $2.44M | Sep 29, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $665.82M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.02B | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | $473.78M | Mar 27, 2026 |
| FY2024 | Dec 31, 2022 | $26.70M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $59.95M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $57.22M | Mar 21, 2023 |
| FY2021 | Jun 30, 2020 | $35.52M | Mar 31, 2022 |
| FY2021 | Jun 30, 2019 | $18.72M | Mar 31, 2022 |
| FY2020 | Jun 30, 2018 | $1.40M | Sep 29, 2020 |
| FY2019 | Jun 30, 2017 | $3.11M | Sep 23, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $154.43M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $53.08M | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | $57.60M | Mar 27, 2026 |
| FY2023 | Dec 31, 2022 | $18.70M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $32.84M | Mar 21, 2023 |
| FY2022 | Dec 31, 2020 | $41.79M | Mar 21, 2023 |
| FY2020 | Jun 30, 2020 | $20.25M | Sep 29, 2020 |
| FY2021 | Dec 31, 2019 | $20.25M | Mar 31, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($52.55M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2024 | ($67.74M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($47.18M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($167.57M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($88.51M) | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | ($57.18M) | Mar 31, 2022 |
| FY2021 | Jul 2, 2020 | $0 | Mar 31, 2022 |
| FY2020 | Jun 30, 2020 | ($41.10M) | Sep 29, 2020 |
| FY2020 | Jun 30, 2019 | ($25.57M) | Sep 29, 2020 |
| FY2019 | Jun 30, 2018 | ($12.94M) | Sep 23, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $735.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $915.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2022 | $267.0K | Mar 31, 2025 |
| FY2022 | Dec 31, 2021 | $12.58M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $17.84M | Mar 31, 2022 |
| FY2020 | Jun 30, 2020 | $24.16M | Sep 29, 2020 |
| FY2020 | Jun 30, 2019 | $21.87M | Sep 29, 2020 |
| FY2019 | Jun 30, 2018 | $1.57M | Sep 23, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $5.15M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $14.61M | Apr 1, 2024 |
| FY2021 | Dec 31, 2021 | $17.31M | Mar 31, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 27, 2026 |
| FY2023 | Dec 31, 2022 | (546) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (24) | Mar 21, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 27, 2026 |
| FY2023 | Dec 31, 2022 | (546) | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 52.99M | Mar 31, 2025 |
| FY2024 | Feb 9, 2024 | 38.04M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | 34.42M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 230,140 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 1.55M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | 19.90M | Mar 31, 2022 |
| FY2020 | Jun 30, 2020 | 13.26M | Sep 29, 2020 |
| FY2020 | Jun 30, 2019 | 10.59M | Sep 29, 2020 |
| FY2019 | Jun 30, 2018 | 4.92M | Sep 23, 2019 |